Kyverna Therapeutics (KYTX) Income towards Parent Company (2023 - 2026)

Kyverna Therapeutics' Income towards Parent Company history runs 4 years deep, the most recent figure standing at -$74.2 million for Q1 2026.

• Quarterly Income towards Parent Company fell 62.83% year-over-year to -$74.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$212.1 million (down 24.3% YoY) and the FY2025 annual result came in at -$204.6 million, down 56.97% from the prior year.
• Income towards Parent Company was -$74.2 million for Q1 2026 at Kyverna Therapeutics, down from -$40.9 million in the prior quarter.
• Across five years, Income towards Parent Company topped out at -$11.7 million in Q1 2023 and bottomed at -$74.2 million in Q1 2026.
• A 4-year average of -$36.3 million and a median of -$40.9 million in 2025 frame the typical range for Income towards Parent Company.
• Annual changes were most pronounced in 2024 — Income towards Parent Company tumbled 203.32% — and 2025, when it fell 1.11%.
• Kyverna Therapeutics' Income towards Parent Company stood at -$19.0 million in 2023, then plunged by 112.69% to -$40.4 million in 2024, then fell by 1.11% to -$40.9 million in 2025, then slumped by 81.45% to -$74.2 million in 2026.
• Business Quant data shows KYTX's Income towards Parent Company at -$74.2 million in Q1 2026, -$40.9 million in Q4 2025, and -$52.8 million in Q3 2025.